Form 4: Xeris COO Trust Distributes 2,000 Shares
Insider Transaction
Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch's trust distributed 2,000 common shares to a beneficiary on September 11, 2025, with no sale occurring.
Summary
- Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc. (XERS), reported a change in beneficial ownership.
- On September 11, 2025, the Charles R. McCulloch Trust, for which Mr. McCulloch is a trustee, distributed 2,000 shares of Xeris common stock to a trust beneficiary.
- This transaction was a distribution and not a sale, with a reported price of $0 per share.
- Following this transaction, Mr. McCulloch directly beneficially owns 1,701,159 shares of common stock.
- Additionally, 25,000 shares are indirectly beneficially owned by his spouse.
- Mr. McCulloch disclaims beneficial ownership of the distributed shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The filing is a standard Form 4 reporting an internal trust distribution of a small number of shares, with no sale occurring. It provides factual information about insider ownership changes but does not reflect positively or negatively on the company's operational or financial performance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.
Industry Context
This Form 4 filing reports a routine insider transaction involving a trust distribution, which is common for executives managing personal holdings. It does not provide insights into broader industry trends or competitive positioning within the biopharmaceutical sector.
Related Party Transactions
- The distribution of 2,000 shares from the Charles R. McCulloch Trust to a beneficiary, where Kevin McCulloch is the trustee, represents a transaction involving a related party (the trust and its beneficiaries).
Stakeholder Impact
- Shareholders: Minimal impact due to the small number of shares involved and the nature of the transaction (internal trust distribution, no market sale).
- Management: Reflects a routine adjustment in personal holdings by a key executive.
Key Dates
| Date | Description |
|---|---|
| 09/11/2025 | Date of transaction where 2,000 shares were distributed from the Charles R. McCulloch Trust. |
| 09/15/2025 | Date the Form 4 filing was signed by Beth Hecht, Attorney-in-Fact for Kevin McCulloch. |
Keywords
Xeris Biopharma Holdings, XERS, Kevin McCulloch, Insider Transaction, Form 4, Beneficial Ownership, Common Stock, Trust Distribution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.